E-ISSN 2231-3206
 
2025, Vol: 15, Issue: 6
15 / 6Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

NJPPP Manuscript Submission Form

Letter to the Editor 


Let us discuss the COVID-19 vaccine for children

Sonia Gulia, Kusum K. Rohilla, Mahendra Kumar, Raman Sharma.


Abstract
A large number of COVID-19 vaccinations are now being licensed for use in children, even though the majority of them are exclusively intended for adults (18 years and older). When creating their COVID-19 immunization policies and programs, countries should consider the individual and population benefits of immunizing children and adolescents in their unique epidemiological. Immunizing children and adolescents is less urgent than immunizing older individuals, those with chronic health conditions, and healthcare professionals because they typically have milder disease compared to adults, unless they are in a group at increased risk of severe COVID-19.

Key words: Immunization; COVID-19 vaccine; Children; Adolescents.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Sonia Gulia
Articles by Kusum K. Rohilla
Articles by Mahendra Kumar
Articles by Raman Sharma
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Gulia S, Rohilla KK, Kumar M, Sharma R. Let us discuss the COVID-19 vaccine for children. doi:10.5455/NJPPP.2025.v15.i6.16

Web Style

Gulia S, Rohilla KK, Kumar M, Sharma R. Let us discuss the COVID-19 vaccine for children. https://www.njppp.com/?mno=125882 [Access: November 02, 2025]. doi:10.5455/NJPPP.2025.v15.i6.16

AMA (American Medical Association) Style

Gulia S, Rohilla KK, Kumar M, Sharma R. Let us discuss the COVID-19 vaccine for children. doi:10.5455/NJPPP.2025.v15.i6.16


Vancouver/ICMJE Style

Gulia S, Rohilla KK, Kumar M, Sharma R. Let us discuss the COVID-19 vaccine for children. doi:10.5455/NJPPP.2025.v15.i6.16


Harvard Style

Gulia, S., Rohilla, . K. K., Kumar, . M. & Sharma, . R. (2025) Let us discuss the COVID-19 vaccine for children. doi:10.5455/NJPPP.2025.v15.i6.16


Turabian Style

Gulia, Sonia, Kusum K. Rohilla, Mahendra Kumar, and Raman Sharma. 2025. Let us discuss the COVID-19 vaccine for children. doi:10.5455/NJPPP.2025.v15.i6.16


Chicago Style

Gulia, Sonia, Kusum K. Rohilla, Mahendra Kumar, and Raman Sharma. "Let us discuss the COVID-19 vaccine for children." doi:10.5455/NJPPP.2025.v15.i6.16


MLA (The Modern Language Association) Style

Gulia, Sonia, Kusum K. Rohilla, Mahendra Kumar, and Raman Sharma. "Let us discuss the COVID-19 vaccine for children." doi:10.5455/NJPPP.2025.v15.i6.16


APA (American Psychological Association) Style

Gulia, S., Rohilla, . K. K., Kumar, . M. & Sharma, . R. (2025) Let us discuss the COVID-19 vaccine for children. doi:10.5455/NJPPP.2025.v15.i6.16


Author LoginReviewer LoginAbout PublisherOpen Access PolicyEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

About the JournalThe National Journal of Physiology, Pharmacy and Pharmacology (NJPPP) is a peer-reviewed, open-access journal dedicated to advancing rese ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information

Eldaghayes Publisher

www.eldaghayes.com 
 

All correspondence should be addressed to:

National Journal of Physiology, Pharmacy and Pharmacology

Email: info@eldaghayes.com